Singular Genomics Systems EBIT

Singular Genomics Systems (OMIC) currently reports a EBIT of $-92M as of September 2024. That compares with $-95M in the prior-year period — up 3.0% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore Singular Genomics Systems's EBIT history and peer comparisons.

Singular Genomics Systems's EBIT increased from $-95M to $-92M — a 3.0% year-over-year increase (period ending September 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Singular Genomics Systems's EBIT of $-92M is lower than the Healthcare sector average of $22B. That is roughly 100.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Singular Genomics Systems reported $-92M in EBIT as of September 2024. That compares with $-95M in the prior-year period — up 3.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-92M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for Singular Genomics Systems, and consider following OMIC for alerts when major investors trade the stock.